HÜRMÜZ, P. Et Al. 2021. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.39, no.6 .

HÜRMÜZ, P., ÖZYİĞİT, G., Kilickap, S., BEDÜK ESEN, Ç. S., AKDOĞAN, B., Ozen, H., ... Akyol, F.(2021). Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.39, no.6.

HÜRMÜZ, PERVİN Et Al. "Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?," UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.39, no.6, 2021

HÜRMÜZ, PERVİN Et Al. "Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?." UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.39, no.6, 2021

HÜRMÜZ, P. Et Al. (2021) . "Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?." UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.39, no.6.

@article{article, author={PERVİN HÜRMÜZ Et Al. }, title={Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?}, journal={UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}, year=2021}